Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression

Journal of the National Cancer Institute

Volumn 89, Issue 3, 1997, Pages 219-227

  Grossfeld, Gary D ^a   Ginsberg, David A ^a   Stein, John P ^a   Bochner, Bernard H ^a   Esrig, David ^a   Groshen, Susan ^a   Dunn, Meleana ^a   Nichols, Peter W ^a   Taylor, Clive R ^a   Skinner, Donald G ^a   Cote, Richard J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOSPONDIN;

ANGIOGENESIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 18744423089     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.3.219     Document Type: Article

References (42)

1. Walz DA. Thrombospondin as a mediator of cancer cell adhesion in metastasis. Cancer Metastasis Rev 1992;11:313-24.
2. Bornstein P. Thrombospondins: structure and regulation of expression [published erratum appears in FASEB J 1993;7:237]. FASEB J 1992;6: 3290-9.
3. Lahav J. The functions of thrombospondin and its involvement in physiology and pathophysiology. Biochim Biophys Acta 1993;1182:1-14.
4. Taraboletti G, Roberts D, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990;111:765-72.
5. Taraboletti G, Roberts DD, Liotta LA. Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J Cell Biol 1987;105:2409-15.
6. Nickoloff BJ, Mitra RS, Riser BL, Dixit VM, Varani J. Modulation of keratinocyte motility. Correlation with production of extracellular matrix molecules in response to growth promoting and antiproliferative factors. Am J Pathol 1988;132:543-51.
7. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, Sage EH. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J Histochem Cytochem 1993;41:1467-77.
8. Liska DJ, Hawkins R, Wikstrom K, Bornstein P. Modulation of thrombospondin expression during differentiation of embryonal carcinoma cells. J Cell Physiol 1994;158:495-505.
9. Corless CL, Mendoza A, Collins T, Lawler J. Colocalization of thrombospondin and syndecan during murine development. Dev Dyn 1992;193:346-58.
10. Varani J, Dixit VM, Fligiel SE, McKeever PE, Carey TE. Thrombospondin-induced attachment and spreading of human squamous carcinoma cells. Exp Cell Res 1986;167:376-90.
11. Roberts DD, Sherwood JA, Ginsburg V. Platelet thrombospondin mediates attachment and spreading of human melanoma cells. J Cell Biol 1987;104: 131-9.
12. Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ. Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 1987;47: 4130-3.
13. Wong SY, Purdie AT, Han P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. Am J Pathol 1992;140:1473-82.
14. Riser BL, Varani J, O'Rourke K, Dixit VM. Thrombospondin binding by human squamous carcinoma and melanoma cells: relationship to biological activity. Exp Cell Res 1988;174:319-29.
15. Castle VP, Ou X, O'Rourke K, Dixit VM. High level thrombospondin 1 expression in two NIH 3T3 cloned lines confers serum- and anchorage-independent growth. J Biol Chem 1993;268:2899-903.
16. Tuszynski GP, Nicosia RF. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab Invest 1994;70:228-33.
17. Clezardin P, Frappart L, Clerget M, Pechoux C, Delmas PD. Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. Cancer Res 1993;53:1421-30.
18. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994;59:191-5.
19. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54:6504-11.
20. Mettouchi A, Cabon F, Montreau N, Vernier P, Mercier G, Blangy D, et al. SPARC and thrombospondin genes are repressed by c-jun oncogene in rat embryo fibroblasts. EMBO J 1994;13:5668-78.
21. Iruela-Arispe ML, Bornstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A 1991;88:5026-30.
22. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
23. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265:1582-4.
24. Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Acta Chir Scand 1965;130:371-8.
25. Hermanek P, Sobin LH, editors. TNM classification of malignant tumors. 4th ed. New York: Springer-Verlag, 1987:133-4.
26. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
27. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-12.
28. Lawler J, Derick LH, Connolly JE, Chen JH, Chao FC. The structure of human platelet thrombospondin. J Biol Chem 1985;260:3762-72.
29. Grossfeld GD, Shi SR, Ginsberg DA, Rich KA, Skinner DG, Taylor CR, et al. Immunohistochemical detection of thrombospondin-1 in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 1996;44:761-6.
30. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Palma PD, Caffo O, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
31. Miller RG. Survival analysis. New York: John Wiley, 1981.
32. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993;88:400-9.
33. Zar JH. Contingency tables, chapt 6. Biostatistical analysis. Englewood Cliffs (NJ): Prentice-Hall, 1974:59-69.
34. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989;56:345-55.
35. BenEzra D, Griffin BW, Maftzir G, Aharonov O. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. Invest Ophthalmol Vis Sci 1993;34:3601-8.
36. Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994;124:183-93.
37. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
38. Esrig D, Spruck CH 3d, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143: 1389-97.
39. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
40. Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, et al. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 1994;145:702-14.
41. Strauss BE, Haas M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem Biophys Res Commun 1995;217:333-40.
42. Le Querrec A, Duval D, Tobelem G. Tumour angiogenesis. Baillieres Clin Haematol 1993;6:711-30.